Connect with us

Medical Research

New Study: Cannabinoid Agonist Treatment to Effectively Reduce Cannabis Dependence

Jocelyn Roman

Published

on

New Study: Cannabinoid Agonist Treatment to Effectively Reduce Cannabis Dependence
- Ad -

Given the known health benefits of recreational marijuana use, there’s another side to said uses that has not been under the spotlight. Turns out, a number of consumers have become cannabis-dependent.

That said, researchers, Nicolas Lintzeries, MBBS, PhD, Anjali Bhardwaj, PhD, Llewellyn Mills, PhD, et al. wanted to see whether cannabinoid agonist drug, which in this case is called “nabiximols,” with “psychosocial serves” reduces cannabis dependence.

For the purpose of this study, 128 participants have been placed in either the placebo or control group and have been administered nabiximols for a 12-week period. Said participants were supposedly between the ages 18 and 64 and were deemed to have cannabis dependence that required further treatment. The control group was given 32 sprays daily.

When participants were not taking recreational cannabis, they not only reported their use of the illicit drug during the allotted time frame, but also, “other outcomes […] periods of abstinence, withdrawal, cravings, and problems, safety parameters, health status.”

Here’s what the researchers had to say regarding the entirety of the study and its results:

“Our study demonstrates that cannabinoid agonist treatment, in combination with psychosocial interventions, reduced illicit cannabis use in patients with cannabis dependence who are seeking treatment. […] The reductions […] and safer route of administration suggest the harm reduction benefits of cannabinoid agonist treatment.” Not to forget, “fewer days of illicit cannabis use compared with placebo.”

Given said results, it is important to be aware of the fact that of the selected participants, only half engaged in the full 12-weeks and that abstinence from illicit cannabis was only experienced by a small fraction of patients. That said, said drug use cannot be generalized to all patients.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com